HIMS insider ownership: who sold, why, and what they still hold

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Oluyemi Okupe Chief Financial Officer	2,000	$29.70	0.8%	241K	Oct 1, 2026	Oct 2, 2026

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Soleil Boughton Chief Legal Officer	3,461	$29.17	1.1%	301K	Sep 30, 2026	Oct 2, 2026

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Oluyemi Okupe Chief Financial Officer	29,277	$29.95	11%	243K	Sep 22, 2026	Sep 23, 2026

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Oluyemi Okupe Chief Financial Officer	12,313	$28.82	4.6%	258K	Sep 17, 2026	Sep 18, 2026

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Soleil Boughton Chief Legal Officer	6,236	$27.86	2.0%	304K	Sep 16, 2026	Sep 17, 2026

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Michael Chi Chief Operating Officer	14,027	$28.39	3.0%	456K	Sep 15, 2026	Sep 17, 2026
Mohamed Elshenawy CTO	7,954	$28.39	4.1%	186K	Sep 15, 2026	Sep 17, 2026

What stands out

David Wells bought 48K shares for $1.2M, first on May 26, 2026.Purchase, May 26, 2026

Garcia Perez sold 2.5K shares (3.0% of starting holdings), but 3.7K more vested, so the stake grew (from 83K to 84K).Largest sale, Dec 9, 2025

Tax withholding outweighed market sales: the company withheld $59.1M of officers' and directors' shares for taxes, against $31.2M sold on the open market. The largest was Andrew Dudum ($21.1M withheld).Largest withholding, Mar 13, 2026

Percentages cover 8 of 18 officers and directors. 10 are left out

Left out: Andrew Dudum (holdings couldn't be fully reconciled); Michael Chi, Patrick Carroll, Soleil Boughton, Oluyemi Okupe, Deborah Autor and Irene Becklund (most of their shares vested during the period, so a percentage would mislead); Mohamed Elshenawy, Nader Kabbani and Kofi Amoo-Gottfried (held no vested shares at the start).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Each bar is the insider's vested stake at the start of the period (Oct 8, 2025). The gold part is what they sold.

SoldRest of starting stakeAdded during the period

Andrew Dudum

Chief Executive Officer, Director

No bar: holdings couldn't be fully reconciled.

$11.0MDisclosed plan

Oluyemi Okupe

Chief Financial Officer

Sold 57% of the shares held or received (after tax withholding) during the period†. No bar against the starting stake: most of these shares arrived during the period.

$10.3MDisclosed plan

Michael Chi

Chief Operating Officer

Sold 23% of the shares held or received (after tax withholding) during the period†. No bar against the starting stake: most of these shares arrived during the period.

$3.8MDisclosed plan

Soleil Boughton

Chief Legal Officer

Sold 18% of the shares held or received (after tax withholding) during the period†. No bar against the starting stake: most of these shares arrived during the period.

$2.0MDisclosed plan

Patrick Carroll

Chief Medical Officer

Sold 15% of the shares held or received (after tax withholding) during the period†. No bar against the starting stake: most of these shares arrived during the period.

$1.2MDisclosed plan

All 9 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosed

Common questions

Is the Hims & Hers Health CEO selling stock?

Yes. Andrew Dudum sold 176K shares ($11.0M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Hims & Hers Health insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 99.7% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 0.3% had no disclosed plan. A trading plan schedules sales in advance.

Are any Hims & Hers Health insiders buying?

Yes. 1 officer or director reported 1 purchase in the past 12 months (Form 4 code P, which includes private purchases).

How much of their stake did Hims & Hers Health insiders sell?

About 0.2% overall. As a group they ended with more shares than they started with. These figures leave out Andrew Dudum, the largest holder (holdings couldn't be fully reconciled). That covers the 12 months to Oct 8, 2026 and counts vested shares reported on SEC Forms 3, 4 and 5, which is not an insider's whole wealth.

The evidence

Who sold9 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Andrew Dudum Chief Executive Officer, Director	$11.0M 176K shares	i No percentage: holdings couldn't be fully reconciled.	Disclosed plan
Oluyemi Okupe Chief Financial Officer	$10.3M 323K shares	57%† i † Most of the shares Oluyemi Okupe sold arrived during the period, so this is shares sold as a share of the 78K held at the start plus the 904K received, less 418K withheld by the company for taxes.	Disclosed plan
Michael Chi Chief Operating Officer	$3.8M 140K shares	23%† i † Most of the shares Michael Chi sold arrived during the period, so this is shares sold as a share of the 291K held at the start plus the 683K received, less 373K withheld by the company for taxes.	Disclosed plan
Soleil Boughton Chief Legal Officer	$2.0M 68K shares	18%† i † Most of the shares Soleil Boughton sold arrived during the period, so this is shares sold as a share of the 164K held at the start plus the 441K received, less 236K withheld by the company for taxes.	Disclosed plan
Patrick Carroll Chief Medical Officer	$1.2M 34K shares	15%† i † Most of the shares Patrick Carroll sold arrived during the period, so this is shares sold as a share of the 170K held at the start plus the 89K received, less 29K withheld by the company for taxes.	Disclosed plan
Mohamed Elshenawy CTO	$1.2M 38K shares	17%† i † Most of the shares Mohamed Elshenawy sold arrived during the period, so this is shares sold as a share of the 0 held at the start plus the 471K received, less 247K withheld by the company for taxes.	Disclosed plan
Irene Becklund Pao	$816K 26K shares	65%† i † Most of the shares Irene Becklund sold arrived during the period, so this is shares sold as a share of the 1.4K held at the start plus the 66K received, less 27K withheld by the company for taxes.	Disclosed plan
Deborah Autor Chief Policy Officer, Director	$726K 24K shares	33%† i † Most of the shares Deborah Autor sold arrived during the period, so this is shares sold as a share of the 6.2K held at the start plus the 109K received, less 43K withheld by the company for taxes.	Disclosed plan
Garcia Perez Director	$98K 2.5K shares	3.0%	No plan disclosed

The full ownership picture17 of 18 insiders fully reconciled · 16 officers and directors

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 8, 2025

Sold

Held Oct 8, 2026

Still held

Andrew Dudum

Holdings couldn't be fully reconciled. A footnote describes a transfer or distribution between related entities, but the amounts could not be matched to the balance change. Largest: +1,954,379 shares on Nov 12, 2025 (AD 2023 GRAT dated 9-5-2023). See the filing Sales and other transactions for Andrew Dudum are complete.

Chief Executive Officer, Director

n/a

−176K

n/a

Vesting, gifts, unvested awards and holding lines for Andrew Dudum

+764Kshares vested or exercised

−463Kgifted (net of own trusts)

−782Kwithheld by the company for taxes

1.30M → 1.07Munvested awards, start → end

Includes unvested RSUs, amount not disclosed.
In-kind distributions to the fund's own investors are labeled as distributions, not sales.
Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Holdings couldn't be fully reconciled. A footnote describes a transfer or distribution between related entities, but the amounts could not be matched to the balance change. Largest: +1,954,379 shares on Nov 12, 2025 (AD 2023 GRAT dated 9-5-2023). The balances below are as reported, not verified totals.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Class A Common Stock	95,315	1,033,177
Dudum Family Heritage Trust UAD 8-10-2021	Class A Common Stock	2,214,769	2,214,769
AD 2023 GRAT dated 9-5-2023	Class A Common Stock	1,584,506	1,954,379
AD 2021 GRAT dated 11-1-2021	Class A Common Stock	1,286,627	1,049,692
AD 2022 GRAT 3 dated 11-28-2022	Class A Common Stock	1,194,545	1,078,549
Andrew Dudum 2015 Trust Dated July 2, 2015	Class A Common Stock	1,016,871	573,202
AD 2022 GRAT 2 dated 9/7/2022	Class A Common Stock	829,185	791,117
AD 2022 GRAT	Class A Common Stock	508,030	463,289
AD 2021 GRAT 2 dated 11-1-2021	Class A Common Stock	321,657	262,423
AD 2025 GRAT dated 5-27-2025	Class A Common Stock	186,723	42,993
Dudum Family Community Property Trust	Class A Common Stock	95,058	470,457
Richard M. Dudum Irrevocable 1 U/A dtd 10/15/1997	Class A Common Stock	1,500	1,500
Dudum Legacy 2021 Trust	Class A Common Stock	0	103,406
Dudum Family 2021 Trust	Class A Common Stock	0	3,004,071
Andrew Dudum 2015 Trust Dated July 2, 2015	Class V Common Stock	7,791,484	8,377,623
AD 2023 GRAT dated 9-5-2023	Class V Common Stock	586,139	0

Additional holdings last reported Jul 19, 2023, not confirmed since: 9,401,943 shares. Not included in any total or percentage on this page.

Atomic Labs II, L.P, Class A Common Stock: 8,280,910 shares, last reported Sep 15, 2021
AD GRAT dated 8/31/20, Class A Common Stock: 1,121,033 shares, last reported Jul 19, 2023

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
431,395	$2.43	Jun 16, 2030	$11.8M
17,005	$2.43	Jun 16, 2030	$464K

Estimate: options held × ($29.70 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Melissa Baird

Chief Operating Officer

805K

no sales

Vesting, gifts, unvested awards and holding lines for Melissa Baird

0shares vested or exercised

0gifted (net of own trusts)

717K → 717Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Class A Common Stock	805,083	805,083

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
54,556	$0.40	Mar 28, 2028	$1.6M
22,569	$1.75	Nov 5, 2029	$631K
737,894	$2.43	May 12, 2030	$20.1M
1,581,288	$5.01	Feb 23, 2032	$39.0M
693,795	$2.43	May 13, 2030	$18.9M

Estimate: options held × ($29.70 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Michael Chi

Minor difference of 540 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

Chief Operating Officer

291K

−140K

457K

not meaningful

Vesting, gifts, unvested awards and holding lines for Michael Chi

+318Kshares vested or exercised

−5Kgifted (net of own trusts)

−373Kwithheld by the company for taxes

524K → 584Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Class A Common Stock	291,439	456,660

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
174,042	$5.01	Feb 24, 2032	$4.3M
115,362	$6.82	Aug 10, 2032	$2.6M
7,800	$13.90	May 27, 2031	$123K
47,106	$11.53	Mar 1, 2033	$856K

Estimate: options held × ($29.70 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Reconciliation: minor difference of 540 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

David Wells

Director

176K

230K

no sales

Vesting, gifts, unvested awards and holding lines for David Wells

+5.4Kshares vested or exercised

0gifted (net of own trusts)

3.7K → 8.2Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Class A Common Stock	176,017	229,808

Patrick Carroll

Minor difference of 1,440 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Chief Medical Officer

170K

−34K

198K

not meaningful

Vesting, gifts, unvested awards and holding lines for Patrick Carroll

+89Kshares vested or exercised

0gifted (net of own trusts)

−29Kwithheld by the company for taxes

142K → 204Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Class A Common Stock	169,940	197,847

Reconciliation: minor difference of 1,440 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Soleil Boughton

Includes unvested RSUs, amount not disclosed.

Chief Legal Officer

164K

−68K

301K

not meaningful

Vesting, gifts, unvested awards and holding lines for Soleil Boughton

+167Kshares vested or exercised

0gifted (net of own trusts)

−236Kwithheld by the company for taxes

303K → 323Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Class A Common Stock	163,767	300,809

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
113,769	$2.43	May 12, 2030	$3.1M
644,154	$5.01	Feb 23, 2032	$15.9M

Estimate: options held × ($29.70 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Christopher Payne

Director

130K

145K

no sales

Vesting, gifts, unvested awards and holding lines for Christopher Payne

+15Kshares vested or exercised

0gifted (net of own trusts)

24K → 18Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Class A Common Stock	19,975	34,863
Payne Family Trust dtd 09/17/2020	Class A Common Stock	110,000	110,000

Garcia Perez

Director

83K

−2.5K

84K

+1.4%

Vesting, gifts, unvested awards and holding lines for Garcia Perez

+3.7Kshares vested or exercised

0gifted (net of own trusts)

3.7K → 8.2Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Class A Common Stock	82,666	83,822

Oluyemi Okupe

Minor difference of 1,481 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer). Includes unvested RSUs, amount not disclosed.

Chief Financial Officer

78K

−323K

242K

not meaningful

Vesting, gifts, unvested awards and holding lines for Oluyemi Okupe

+493Kshares vested or exercised

0gifted (net of own trusts)

−418Kwithheld by the company for taxes

605K → 553Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Class A Common Stock	70,232	234,527
Oluyemi Okupe Separate Property Trust dtd 9-1-2021	Class A Common Stock	7,853	7,853

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
66,872	$5.01	Feb 23, 2032	$1.7M
35,996	$11.53	Mar 1, 2033	$654K

Estimate: options held × ($29.70 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Reconciliation: minor difference of 1,481 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Delos Cosgrove

Director

64K

68K

no sales

Vesting, gifts, unvested awards and holding lines for Delos Cosgrove

+3.7Kshares vested or exercised

0gifted (net of own trusts)

3.7K → 8.2Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Class A Common Stock	64,339	67,995

Christiane Pendarvis

Director

37K

55K

no sales

Vesting, gifts, unvested awards and holding lines for Christiane Pendarvis

+19Kshares vested or exercised

0gifted (net of own trusts)

19K → 0unvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Class A Common Stock	36,563	55,430

Anja Manuel

Director

25K

39K

no sales

Vesting, gifts, unvested awards and holding lines for Anja Manuel

+14Kshares vested or exercised

0gifted (net of own trusts)

24K → 18Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Class A Common Stock	24,975	38,671

Kare Schultz

Director

16K

26K

no sales

Vesting, gifts, unvested awards and holding lines for Kare Schultz

+10Kshares vested or exercised

0gifted (net of own trusts)

17K → 15Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Class A Common Stock	15,741	26,020

Deborah Autor

Chief Policy Officer, Director

6.2K

−24K

49K

not meaningful

Vesting, gifts, unvested awards and holding lines for Deborah Autor

+109Kshares vested or exercised

0gifted (net of own trusts)

−43Kwithheld by the company for taxes

25K → 450Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Class A Common Stock	6,175	48,961

Irene Becklund

Pao

1.4K

−26K

14K

not meaningful

Vesting, gifts, unvested awards and holding lines for Irene Becklund

+66Kshares vested or exercised

0gifted (net of own trusts)

−27Kwithheld by the company for taxes

106K → 102Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Class A Common Stock	1,418	13,985

Mohamed Elshenawy

CTO

−38K

186K

not meaningful

Vesting, gifts, unvested awards and holding lines for Mohamed Elshenawy

+471Kshares vested or exercised

0gifted (net of own trusts)

−247Kwithheld by the company for taxes

1.04M → 2.14Munvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Class A Common Stock	0	185,556

17 of 18 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (14 exactly, 3 with a minor or footnoted difference). For 1 we show sales but not holdings; the ! icon on that row explains why. Percentages cover 8 of 18 officers and directors. Left out: Andrew Dudum (holdings couldn't be fully reconciled); Michael Chi, Patrick Carroll, Soleil Boughton, Oluyemi Okupe, Deborah Autor and Irene Becklund (most of their shares vested during the period, so a percentage would mislead); Mohamed Elshenawy, Nader Kabbani and Kofi Amoo-Gottfried (held no vested shares at the start). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.

What explains the selling$31.2M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $31.2M across 830,263 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $31.1M · 99.7%

0.3%

The lighter segment is sales with no plan disclosed in the filing ($98K), including tax-related sales outside a plan.

No plan disclosed · $98K

Sales with no 10b5-1 plan and no tax reference in the filing. $98K of it is Garcia Perez. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Garcia Perez, Dec 9, 2025

Taxes

2,155,303 shares ($59.1M) were withheld by the company for taxes, which isn't a market sale.

Purchases · 1 buyer (1 trade)

1 officer or director bought shares in this period, in 1 trade(Form 4 code P). Across all their filings on record there are 11 purchase trades.

Charitable gifts · 5K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Andrew Dudum Chief Executive Officer, Director	176K	$11.0M	100%	35%	Oct 16, 2025 to Oct 16, 2025
Oluyemi Okupe Chief Financial Officer	323K	$10.3M	100%	33%	Oct 17, 2025 to Oct 1, 2026
Michael Chi Chief Operating Officer	140K	$3.8M	100%	12%	Oct 10, 2025 to Sep 15, 2026
Soleil Boughton Chief Legal Officer	68K	$2.0M	100%	6%	Oct 13, 2025 to Sep 30, 2026
Patrick Carroll Chief Medical Officer	34K	$1.2M	100%	4%	Dec 17, 2025 to Jun 18, 2026
Mohamed Elshenawy CTO	38K	$1.2M	100%	4%	Jun 17, 2026 to Sep 15, 2026
Irene Becklund Pao	26K	$816K	100%	3%	Dec 17, 2025 to Jun 17, 2026
Deborah Autor Chief Policy Officer, Director	24K	$726K	100%	2%	Dec 17, 2025 to Aug 18, 2026
Garcia Perez Director	2.5K	$98K	0%	0.3%	Dec 9, 2025 to Dec 9, 2025

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$12.0M	$12.0M	$0	$0
Nov 2025	$1.1M	$1.1M	$0	$0
Dec 2025	$2.4M	$2.3M	$0	$98K
Jan 2026	$582K	$582K	$0	$0
Feb 2026	$210K	$210K	$0	$0
Mar 2026	$2.9M	$2.9M	$0	$0
Apr 2026	$2.4M	$2.4M	$0	$0
May 2026	$188K	$188K	$0	$0
Jun 2026	$5.2M	$5.2M	$0	$0
Jul 2026	$491K	$491K	$0	$0
Aug 2026	$1.6M	$1.6M	$0	$0
Sep 2026	$2.2M	$2.2M	$0	$0
Oct 2026	$59K	$59K	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

Less than usual: about a third of the 5-year average. 9 insiders sold; the average is 7 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 8, 2026 Latest 12 months	830K	9	$31.2M
Oct 8, 2025 1 year earlier	5.46M	9	$217M
Oct 8, 2024 2 years earlier	6.53M	10	$105M
Oct 9, 2023 3 years earlier	1.12M	8	$9.9M
Oct 9, 2022 4 years earlier	286K	4	$1.4M
Oct 9, 2021 5 years earlier	328K	5	$3.5M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty1 insider whose holdings couldn't be fully reconciled

Andrew Dudum: holdings couldn't be fully reconciled (difference of 4,808,332 shares). A footnote describes a transfer or distribution between related entities, but the amounts could not be matched to the balance change. Largest: +1,954,379 shares on Nov 12, 2025 (AD 2023 GRAT dated 9-5-2023). Filing, Nov 12, 2025

Footnote: "This amount reflects 1) an annuity payment-in-kind of 216,266 shares of Class A Common Stock from the AD 2023 GRAT dated 9-5-2023 to the Andrew Dudum 2015 Trust dated July 2, 2015 and 2) a transfer of 586,139 Class A Common Stock to the AD GRAT 2023 dated 9-5-2023 from the Andrew Dudum 2015 Trust dated July 2, 2015."

Michael Chi: minor difference of 540 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Patrick Carroll: minor difference of 1,440 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Oluyemi Okupe: minor difference of 1,481 shares. Difference is stated in footnotes (unreported vesting, exempt acquisition or transfer).

Inferred rename: "AD 2025 GRAT 3 dated 5-27-2025" is treated as the same holder as "AD 2025 GRAT dated 5-27-2025", because the old name was never reported again and the new one opened with the same balance (186,723 shares). Old name, new name

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology741 filings from SEC EDGAR, and how we read them

All 741 Forms 3, 4 and 5 filed for Hims & Hers Health (SEC CIK 1773751) from Jul 17, 2019 to Oct 2, 2026, retrieved from SEC EDGAR on Oct 8, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (20)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Alex Bard	Jun 10, 2024	148,621 shares, last reported balance as of Jun 6, 2024
Lynne O'Keefe	Jun 10, 2024	177,581 shares, last reported balance as of Jun 6, 2024
Ambar Bhattacharyya	Jun 10, 2024	90,985 shares, last reported balance as of Jun 6, 2024
Alex Bard	Jun 10, 2024	5,077,016 shares, last reported balance as of Mar 15, 2024
Kristen Green	Jun 2, 2023	45,248 shares, last reported balance as of Jun 1, 2023
Jules Maltz	Jun 2, 2023	266,923 shares, last reported balance as of Jun 1, 2023
Kristen Green	Jun 2, 2023	9,756,893 shares, last reported balance as of Jun 1, 2023
Jules Maltz	Jun 2, 2023	15,417,020 shares, last reported balance as of Jun 1, 2023
Institutional Venture Management XV, LLC	Mar 6, 2023	15,451,391 shares, last reported balance as of Mar 2, 2023
Jack Abraham	Dec 16, 2021	19,560,737 shares, last reported balance as of Dec 14, 2021
Spencer Lee	Sep 17, 2021	61,935 shares, last reported balance as of Sep 15, 2021
Oaktree Acquisition Holdings, L.P.	Jan 22, 2021	3,773,437 shares, last reported balance as of Jan 20, 2021
Andrea Wong		No balance on record
Alexander Taubman		No balance on record
Anthony Grillo		No balance on record
Patrick McCaney		No balance on record
Mathew Pendo		No balance on record
John Frank		No balance on record
Paul Meister		No balance on record
Zaid Pardesi		No balance on record

Hims & Hers Health insiders sold $31.2M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Common questions

Is the Hims & Hers Health CEO selling stock?

Why are Hims & Hers Health insiders selling?

Are any Hims & Hers Health insiders buying?

How much of their stake did Hims & Hers Health insiders sell?

The evidence

No plan disclosed · $98K

Taxes

Purchases · 1 buyer (1 trade)

Charitable gifts · 5K shares

Sales by month